Saw Palmetto and BPH: What the STEP and CAMUS Trials Actually Found

Saw palmetto (Serenoa repens) is derived from the berries of a small palm native to the southeastern United States. It's been used for prostate symptoms for over a century and generates hundreds of millions in annual supplement sales. The mechanism sounds compelling — it inhibits 5-alpha reductase and has anti-inflammatory properties. But the clinical trial evidence tells a more complicated story.

So Should Men Still Take Saw Palmetto for BPH? Short Answer

For men with moderate-to-severe BPH looking for meaningful symptom relief, the honest answer based on the strongest available evidence is no — the two most rigorous trials ever conducted (STEP and CAMUS) both found saw palmetto performed no better than placebo, even at three times the standard dose sustained over 72 weeks. This is a genuinely important finding to sit with, because it directly contradicts the popular narrative built on earlier, smaller, less rigorous trials, and it means a man relying on saw palmetto instead of an alpha-blocker or 5-ARI for significant urinary symptoms is likely getting a placebo-equivalent effect rather than real symptom control. That said, 'doesn't outperform placebo in a rigorous trial for moderate-severe symptoms' isn't the same as 'has no possible value for anyone' — saw palmetto remains a very low-risk supplement, and men with mild symptoms, men who want to try something before committing to prescription medication with real side effects, or men adding it as one part of a broader lifestyle approach can reasonably continue using it with realistic expectations, as long as they understand the trial evidence doesn't support it as a primary treatment for clinically significant BPH.

What Saw Palmetto Is Supposed to Do

Proposed mechanisms: (1) weak 5-alpha reductase inhibition — reduces DHT production similarly to finasteride but less potently, (2) anti-inflammatory effects — reduces prostate inflammation, (3) alpha-1 adrenergic receptor antagonism — similar to tamsulosin mechanism, (4) anti-proliferative effects on prostate cells. In vitro and animal studies support these mechanisms. The clinical question is whether these mechanisms produce meaningful symptom benefit in men with BPH.

The STEP Trial: The Definitive Answer

The STEP (Saw palmetto for Treatment of Enlarged Prostates) trial, published in NEJM 2006, was a well-designed, double-blind, placebo-controlled RCT with 225 men with moderate-to-severe BPH [2]. Result: saw palmetto 160mg twice daily showed no statistically significant improvement over placebo in IPSS score, urinary flow rate, prostate size, residual urine volume, or quality of life [2]. This was the most rigorous trial conducted.

The CAMUS Trial: Higher Dose, Same Conclusion

The CAMUS trial (2011, JAMA) tested whether higher doses might work where standard doses failed [1]. Men were randomized to escalating doses from 320mg to 960mg/day over 72 weeks. Result: no dose level significantly outperformed placebo on IPSS score, urinary flow, or prostate volume. The conclusion: dose escalation does not rescue saw palmetto efficacy for BPH.

Earlier Meta-Analyses: Why the Confusion?

A 1998 meta-analysis (Wilt et al., JAMA) of 18 mostly short trials (2,939 men) suggested modest benefit: men taking saw palmetto were about 1.7 times as likely to report symptom improvement versus placebo in the six trials that measured it [3]. However, many of these trials were short (4–8 weeks), used heterogeneous extracts with variable liposterol content, lacked adequate blinding, and had small samples. The two subsequent larger, better-designed trials (STEP, CAMUS) consistently found no benefit.

Who Saw Palmetto Might Help

Despite the negative RCT evidence for moderate-severe BPH, some considerations: (1) Men with very mild symptoms (IPSS 0–5) — who may experience placebo benefit and have room for modest real effects, (2) Men who prefer to try supplements before medication, understanding the weak evidence, (3) As part of a broader lifestyle approach — saw palmetto is safe and well-tolerated, and may have modest anti-inflammatory prostate effects even without measuring IPSS improvement.

Saw Palmetto Dosage and What to Look For

• •Standard dose: 160mg twice daily (320mg/day) of liposterol extract standardized to 85–95% fatty acids
• •Higher doses (up to 960mg/day) do not improve efficacy based on the CAMUS trial [1]
• •Extract standardization matters: look for 85–95% fatty acids and sterols on label
• •Hexane vs. CO2 extraction: CO2 extraction may preserve more active compounds (limited evidence)
• •Avoid non-standardized berry powder products — liposterol content is not consistent

Why the STEP and CAMUS Results Surprised So Many People

The gap between the earlier positive meta-analyses and the later definitive negative trials is worth understanding, since it's a useful case study in how supplement evidence quality can be misleading if you only look at the earliest available data. The 1998 Wilt meta-analysis pooled 18 trials that were individually small, often industry-funded, used varying and sometimes poorly standardized extracts, and in several cases had inadequate blinding procedures that could have let both patients and researchers unconsciously bias their symptom reporting. STEP and CAMUS, by contrast, were purpose-built to fix every one of these weaknesses: larger sample sizes, rigorous double-blinding, a single well-standardized extract, and — in CAMUS's case — a dose-escalation design specifically to rule out the possibility that earlier trials simply hadn't used enough saw palmetto. When a supplement's evidence base looks convincing based on a pile of small early studies but then fails to replicate in large, well-controlled trials specifically designed to settle the question, that pattern itself is informative — it's a recognizable signature of publication bias and methodological weakness in the earlier literature rather than a real effect that later studies somehow failed to detect.